We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
-17.79%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.33B
AUM Growth
-$491M
(-27%)
Cap. Flow
-$49.3M
Cap. Flow
% of AUM
-3.7%
Top 10 Holdings %
Top 10 Hldgs %
64.77%
Holding
54
New
6
Increased
6
Reduced
13
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$18.2M |
| 2 |
Pliant Therapeutics
PLRX
|
+$18.2M |
| 3 |
GH Research
GHRS
|
+$15.8M |
| 4 |
CRGX
CARGO Therapeutics
CRGX
|
+$14.7M |
| 5 |
BridgeBio Pharma
BBIO
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$20.2M |
| 2 |
Vaxcyte
PCVX
|
+$20M |
| 3 |
ACLX
Arcellx
ACLX
|
+$16.9M |
| 4 |
ArriVent BioPharma
AVBP
|
+$15.6M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$14.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$1.56B
| $332M | 24.95% |
8,494,151
| – | – |
|
|
2
Edgewise Therapeutics
EWTX
$4.28B
| $90.2M | 6.79% |
4,101,992
+695,458
| +20% | +$18.2M |
|
|
3
BridgeBio Pharma
BBIO
$16.4B
| $69.1M | 5.2% |
2,000,000
+400,000
| +25% | +$13.5M |
|
|
ACLX
4
DELISTED
Arcellx
ACLX
| $68.9M | 5.18% |
1,050,000
-250,000
| -19% | -$16.9M |
|
5
Praxis Precision Medicines
PRAX
$8.11B
| $66.1M | 4.97% |
1,745,000
+51,781
| +3% | +$3.23M |
|
6
NewAmsterdam Pharma
NAMS
$3.26B
| $57.8M | 4.35% |
2,825,000
-425,000
| -13% | -$9.45M |
|
7
Janux Therapeutics
JANX
$912M
| $54M | 4.06% |
2,000,000
-100,000
| -5% | -$3.77M |
|
8
EyePoint Inc
EYPT
$999M
| $45.1M | 3.39% |
8,325,000
| – | – |
|
9
Insmed
INSM
$22.4B
| $40.1M | 3.01% |
525,000
-125,000
| -19% | -$9.56M |
|
|
DRUG
10
Bright Minds Biosciences
DRUG
$697M
| $38.2M | 2.87% |
1,059,331
| – | – |
|
|
BBOT
11
BridgeBio Oncology
BBOT
$659M
| $32.9M | 2.47% |
2,909,000
| – | – |
|
|
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
| $32.5M | 2.45% |
2,261,600
-300,000
| -12% | -$4.91M |
|
|
MRUS
13
DELISTED
Merus
MRUS
| $31.1M | 2.34% |
740,000
| – | – |
|
|
RAPP
14
Rapport Therapeutics
RAPP
$1.96B
| $29.5M | 2.22% |
2,940,921
| – | – |
|
15
Axsome Therapeutics
AXSM
$11.7B
| $29.2M | 2.19% |
250,000
-75,000
| -23% | -$8.54M |
|
16
Pharvaris
PHVS
$2.28B
| $23M | 1.73% |
1,466,460
| – | – |
|
|
17
GH Research
GHRS
$1.92B
| $22.2M | 1.67% |
2,009,482
+1,416,439
| +239% | +$15.8M |
|
18
Arcutis Biotherapeutics
ARQT
$3.48B
| $21.1M | 1.59% |
1,350,000
-475,000
| -26% | -$6.69M |
|
19
Tarsus Pharmaceuticals
TARS
$2.55B
| $20.5M | 1.55% |
400,000
-100,000
| -20% | -$4.94M |
|
20
ARS Pharmaceuticals
SPRY
$579M
| $20.1M | 1.51% |
1,600,000
+1,100,000
| +220% | +$13.2M |
|
|
21
Crinetics Pharmaceuticals
CRNX
$8.88B
| $20.1M | 1.51% |
600,000
-400,000
| -40% | -$14.9M |
|
22
CG Oncology
CGON
$6.1B
| $19M | 1.43% |
775,000
| – | – |
|
|
CRGX
23
DELISTED
CARGO Therapeutics
CRGX
| $13.8M | 1.03% |
3,381,277
+2,198,714
| +186% | +$14.7M |
|
|
ABVX
24
Abivax
ABVX
$10.4B
| $13.3M | 1% |
2,130,000
| – | – |
|
|
ALMS
25
Alumis Inc
ALMS
$3.36B
| $13.2M | 0.99% |
2,147,396
| – | – |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Cormorant Asset Management held 54 positions worth $1.33B, down 27% from $1.82B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Cormorant Asset Management withdrew a net $49.3M in Q1 2025, closing 10 positions and reducing 13 holdings. Its most notable exit was ArriVent BioPharma, an estimated $15.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Pliant Therapeutics worth $4.05M.
- Cormorant Asset Management's largest Q1 2025 buy was Pliant Therapeutics: 3,000,000 shares worth $4.05M.
- Cormorant Asset Management added most to Edgewise Therapeutics in Q1 2025, an estimated $18.2M increase.
- Cormorant Asset Management's biggest Q1 2025 reduction was Avidity Biosciences, cutting an estimated $20.2M.
- Cormorant Asset Management fully exited ArriVent BioPharma in Q1 2025, selling an estimated $15.6M.
- Cormorant Asset Management's ten largest holdings make up 65% of its $1.33B portfolio in Q1 2025.
- Cormorant Asset Management opened 6 new positions and closed 10 in Q1 2025.
- Cormorant Asset Management's portfolio value fell 27% quarter-over-quarter to $1.33B.
Based on Cormorant Asset Management's 13F filing for Q1 2025, filed 15 May 2025.